Johnson & Johnson (JNJ) EBITDA Margin (2009 - 2026)

Johnson & Johnson has disclosed EBITDA Margin across 18 years of filings, most recently posting 26.44% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 26.44%, down 179.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 41.62% (up 1779.0% YoY), and the FY2025 annual result was 42.39%, up 1873.0% from the prior year.
• EBITDA Margin came in at 26.44% for Q1 2026 at Johnson & Johnson, down from 81.68% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 88.12% in Q4 2023 to a low of 15.98% in Q4 2024.
• The 5-year median for EBITDA Margin is 27.36% (2023), against an average of 33.75%.
• Across the five-year window, EBITDA Margin slumped 7214 bps in 2024 and soared 6570 bps in 2025, its largest moves.
• Johnson & Johnson's EBITDA Margin stood at 26.5% in 2022, then soared by 233 bps to 88.12% in 2023, then tumbled by 82 bps to 15.98% in 2024, then surged by 411 bps to 81.68% in 2025, then plunged by 68 bps to 26.44% in 2026.
• The last three EBITDA Margin figures came in at 26.44% (Q1 2026), 81.68% (Q4 2025), and 29.31% (Q3 2025), per Business Quant data.